Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
291 stopped studies mapped to Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and descendants · 82% state a reason
Over the 291 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and…(ULTRA-V) | Phase 2 / Phase 3 | terminated | Jan 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT05465876 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL(PACE-CLL) | Phase 2 | withdrawn | Jul 20, 2022 | Sunnybrook Health Sciences Centre | Funding pulled | Funding |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell… | Phase 1 / Phase 2 | withdrawn | Mar 31, 2017 | Zhujiang Hospital | The company did not offer the appropriate CART services. | Sponsor / business decision |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Jul 27, 2021 | Vincerx Pharma, Inc. | Slow enrollment | Enrollment / accrual |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously… | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | Sumitomo Pharma America, Inc. | Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to… | Other (stated, no rule matched) |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Phase 1 | terminated | Jan 29, 2020 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03659669 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic…(REVEAL) | — | suspended | Sep 6, 2018 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or… | Phase 1 | withdrawn | Mar 21, 2019 | M.D. Anderson Cancer Center | Request by sponsor due to no enrollment of participants on study | Enrollment / accrual |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or… | Phase 1 / Phase 2 | withdrawn | Jul 23, 2019 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve… | Phase 2 | terminated | Feb 4, 2019 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants… | Phase 2 | terminated | Jul 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 3, 2021 | Exelixis | Due to Sponsor reasons. | Other (stated, no rule matched) |
| NCT01013961 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic… | Phase 2 | terminated | Nov 16, 2009 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen… | Early Phase 1 | terminated | Dec 28, 2015 | University of Pennsylvania | Study is terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib… | Phase 2 | terminated | Jan 14, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric… | Phase 1 | withdrawn | Sep 8, 2021 | University of Pennsylvania | No available investigational product | Other (stated, no rule matched) |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | Phase 2 | terminated | Nov 4, 2019 | Weill Medical College of Cornell University | Terminated due to low accrual | Enrollment / accrual |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03919214 | Hypertension Management in Cancer Patients | N/A | terminated | Apr 18, 2019 | Duke University | Initially suspended due to Covid-19. After much consideration, it was determined that we do not… | COVID-19 / pandemic |
| NCT00558961 | Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic…(GL-CLB-001) | Phase 1 / Phase 2 | terminated | Nov 16, 2007 | Jewish General Hospital | Unsatisfactory enrollment | Enrollment / accrual |
| NCT05365100 | A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL | Phase 1 / Phase 2 | withdrawn | May 9, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT05209308 | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL(CORAL) | Phase 2 | withdrawn | Jan 26, 2022 | MEI Pharma, Inc. | Discontinuation of zandelisib development | Other (stated, no rule matched) |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic…(BRIO) | Phase 2 | withdrawn | Dec 12, 2017 | SecuraBio | Reassessing corporate priorities. | Other (stated, no rule matched) |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi… | Phase 1 | terminated | Nov 17, 2014 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | Phase 1 | withdrawn | Jan 4, 2022 | Hutchmed | HUTCHMED has decided to discontinue the HMPL 760 study. | Other (stated, no rule matched) |
| NCT05570188 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic… | Phase 1 / Phase 2 | withdrawn | Oct 6, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer… | N/A | terminated | Oct 22, 2020 | University of Michigan Rogel Cancer Center | accrual difficulties | Enrollment / accrual |
| NCT04655261 | Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection…(FIRST) | — | terminated | Dec 7, 2020 | AbbVie | Lack of Recruitment | Enrollment / accrual |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant… | Phase 1 / Phase 2 | terminated | Aug 7, 2020 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Study terminated early due to business decision. | Sponsor / business decision |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic… | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and… | Phase 1 / Phase 2 | terminated | Dec 20, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With… | Phase 2 | withdrawn | Dec 11, 2020 | Academic and Community Cancer Research United | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected… | COVID-19 / pandemic |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without…(UNITY-NHL) | Phase 2 / Phase 3 | terminated | Jun 8, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in… | Phase 2 | terminated | Jul 2, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for…(VZCLLPI0146) | Phase 2 | terminated | Nov 16, 2010 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT01982175 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia(CLL004) | Phase 2 | suspended | Nov 13, 2013 | Shanghai Zhangjiang Biotechnology Limited Company | recruiting difficulties | Enrollment / accrual |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | Phase 1 | terminated | Dec 7, 2012 | TG Therapeutics, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic… | Phase 2 | terminated | Nov 7, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT04660045 | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Phase 2 | withdrawn | Dec 9, 2020 | Weill Medical College of Cornell University | Company supplying drug/funding ceased support. | Funding |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | terminated | Dec 24, 2019 | National Heart, Lung, and Blood Institute (NHLBI) | Due to unexpected sudden death on study. | Other (stated, no rule matched) |
| NCT04160195 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for… | Phase 1 | terminated | Nov 12, 2019 | National Cancer Institute (NCI) | The original principal investigator left the National Institutes of Health (NCI) and the decision… | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 19, 2024source: clinicaltrials